Read the reports from the American Association of Diabetes Educators National Conference 2019 in
Houston, TX (August 9-12)

< Back to Press

24 April 2023


Parsippany, United States

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense® E3 in the U.S. with a commercial update and outlook on future innovation, as discussed in the recent Eversense CGM Virtual Analyst and Investor Event.

“The last year has really seen our partnership with Senseonics go from strength to strength,” said Rob Schumm, President and CEO of Ascensia Diabetes Care. “At Ascensia we’ve been focused on driving the uptake of this highly differentiated product, and we are encouraged to see more patients accessing its benefits. Meanwhile, Senseonics has been focused on delivering innovation based on the feedback that we both hear from patients. Together, we have an ambitious vision for what the diabetes management of tomorrow looks like, and we are increasingly excited about what the future holds.”

In April 2022, Ascensia launched the Eversense® E3 CGM System for patients in the U.S., shortly after it was approved by the U.S. Food and Drug Administration (FDA). Developed by Senseonics, the system includes the longest lasting CGM sensor available, with up to six-months of wear, compared to just one or two weeks with most CGM systems. Alongside improved longevity, this next-generation system also offers people with diabetes unique and competitive features such as a fully implantable sensor, a removable smart transmitter*, discreet on-body vibe alerts, exceptional accuracy1 and an intuitive smartphone app. Key highlights from the past year include:

U.S. Commercial Highlights

  • Significant coverage success with over 250 million covered lives, including favorable Medicare reimbursement and coverage from nearly all major national insurers
  • Number of Eversense users significantly expanded since the launch of Eversense E3, providing a foundation for the strong growth that we expect in the US this year
  • Continuation of PASS (Payment Assistance and Simple Savings) Program to reduce out-of-pocket expenses for Eversense users with insurance coverage
  • Growing number of certified inserters, supplemented by a network of certified mobile and at-home inserters through the Nurse Practitioner Group partnership
  • Increasing opportunity for people living with type 2 diabetes, with type 2 diabetes patients accounting for half of those using the system
  • Majority of our new users are moving from their current CGM to Eversense
  • Ongoing expansion of our dedicated CGM salesforce to help drive Eversense awareness and adoption

Innovation Outlook

  • ENHANCE pivotal clinical trial for the 365-day sensor is underway, with plans to submit data to the FDA for potential approval, targeted for mid-2024
    • Pediatric cohort has started enrolling, evaluating the use of Eversense in youth
  • Executing plans with a goal to achieve iCGM (integrated CGM) clearance and integration for Eversense with automated insulin delivery (AID) systems
  • The Gemini development program, investigating products with both real-time CGM monitoring and on-demand intermittent scanning to provide increased flexibility for patients
  • Work underway towards the Eversense Freedom system, which captures all the current features and benefits of Eversense but with no on-body components

Last year’s launch was an important landmark in the global partnership between Ascensia and Senseonics, which has supported both patient access to Eversense and the development of future products, by allowing both companies to focus on their core strengths. Senseonics remains responsible for research, development, innovation, and manufacturing while Ascensia is able to leverage its market-leading position in BGM to exclusively lead worldwide marketing and commercialization.

Eversense CGM Systems and the Eversense CGM App are available across the US and select countries in Europe. Please visit for more information. To learn more, please refer to the recent Eversense CGM Virtual Analyst and Investor Event hosted by Ascensia, Senseonics Holdings (NYSE: SENS) and PHC Holdings Corporation (TSE: 6523).



1Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at:

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries.

About Eversense

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see

For more media enquiries, please contact:

Tim Stamper,